Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of JNJ-90301900 with chemoradiation followed by durvalumab in unresectable Stage III non-small cell lung cancer
2024-518276-32-00Phase 2Authorised
- Sponsor
- Johnson & Johnson
- Start
- Mar 2025
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of NBTXR3 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Objective response rate (ORR). Planned start Mar 2025; status: authorised.
02
Drugs
NBTXR3
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-518276-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518276-32-00.